A
Arzeda
Develops enzyme design technology to create entirely novel designer cell factories capable of industry-scale chemical production
About Arzeda
Arzeda is a biotechnology company specializing in the computational design of proteins to create sustainable and high-performance chemicals. Operating in the industrial biotechnology market, Arzeda serves clients across various sectors including chemicals, materials, and consumer goods. The company's business model revolves around leveraging its proprietary technology to design custom proteins and fermentation strains, enabling the production of novel molecules that are otherwise inaccessible through natural diversity or synthetic chemistry. Arzeda generates revenue through partnerships, licensing agreements, and collaborative projects with industry leaders such as Unilever and Amyris. By optimizing and differentiating bioproducts, Arzeda aims to improve economic efficiency and market penetration for its clients. Keywords: computational protein design, sustainable chemicals, biotechnology, industrial production, enzyme design, fermentation strains, novel molecules, partnerships, licensing, market differentiation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- Seattle, United States
- Employees
- 76
- Open positions
- 1
- Dealroom signal
- 83.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Chemistry, Core AI, Synthetic Biology, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, AI Drug Discovery
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Sep 2025 | $7.8M | — | US National Science Foundation | ↗ |
| LATE VCOther financing | Sep 2024 | $38M | $152M | Lewis & Clark Agrifood · Bunge Ventures · Conti Ventures · W.L. Gore & Associates | ↗ |
Growth signals
Latest recorded traffic for Arzeda is 4K monthly website visits, down 66.7% over the last three months. Arzeda's team grew 11.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
WRF Capital
US National Science Foundation
Series A10 investors entered at this stage
OS Fund- BVBioeconomy Capital Sustainable Conversion Ventures
Universal Materials Incubator
Sahsen Ventures- CVConti Ventures
Casdin Capital
Circulate Capital
Lewis & Clark Agrifood- BVBunge Ventures
Bioeconomy Capital
Series B and later4 investors entered at this stage
W.L. Gore & Associates
Sucden Ventures
Sofinnova Partners
Fall Line Capital
Other known investors1 additional known investor
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arzeda on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arzeda’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.